Core Viewpoint - Alibaba Health (00241) has seen its stock price increase by over 30% this month, with a current price of 6.86 HKD, marking a rise of 4.89% at the time of reporting [1] Group 1: Product Launch - Alibaba Health has exclusively launched a groundbreaking treatment for infant vascular tumors, a modified new drug called Timolol Maleate Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. over 12 years [1] - The drug is set to be approved for market release by the National Medical Products Administration by September 30, 2025, making it the first and only approved topical gel for treating "proliferative superficial infantile hemangiomas" globally [1] Group 2: Market Recognition - The product Beimeijing® has received authoritative recognition from the national drug pricing management system, which issued the first overseas drug price certificate for it on January 13 [1] - This certification establishes a traceable and referable price benchmark for Chinese innovative drugs in the international market, filling a gap in the certification of commodity drug prices for international applications [1]

格隆汇1月13日丨漱玉平民(301017.SZ)公布，持股5%以上股东阿里健康科技(中国)有限公司（简称"阿 里健康"）持有公司股份27,039,100股（占公司总股本比例为6.67%），计划在本公告发布之日起15个交 易日后的3个月内（即2026年2月4日至2026年4月30日），以集中竞价和/或大宗交易方式共计减持本公 司股份不超过8,107,214股，占公司总股本的2%。 ...

来源：金综科技 本次减持计划实施期间，公司董事会将督促上述股东严格遵守相应的法律法规、部门规章、规范性文件 的规定，持续关注股东股份减持计划实施的进展情况，及时履行信息披露义务。 特别声明：以上内容仅代表作者本人的观点或立场，不代表新浪财经头条的观点或立场。如因作品内 容、版权或其他问题需要与新浪财经头条联系的，请于上述内容发布后的30天内进行。 本次减持计划实施具有不确定性，本次减持计划将根据自身情况、市场情况、公司股价情况等情形决定 是否实施本次股份减持计划，存在减持时间、数量、价格的不确定性，也存在是否按期实施完成的不确 定性。 此外，本次股份减持计划为股东的正常减持行为。本次减持计划的实施不会导致公司控制权发生变更， 不会对公司治理结构及持续性经营产生影响。 1月13日，漱玉平民(301017.SZ)发布公告，持股5%以上股东阿里健康科技(中国)有限公司(以下简称"阿 里健康")计划在本公告发布之日起15个交易日后的3个月内(即2026年2月4日至2026年4月30日)，以集中 竞价和/或大宗交易方式共计减持公司股份不超过810.72万股，占公司总股本的2%。 ...

人民财讯1月13日电，漱玉平民（301017）1月13日公告，持股6.67%的股东阿里健康科技(中国)有限公 司(简称"阿里健康")计划15个交易日后的3个月内，以集中竞价或大宗交易方式共计减持公司股份不超 过810.72万股，占公司总股本的2%。 ...

来源：智通财经 1月13日，港股开盘，恒生指数涨1.32%，恒生科技指数涨1.93%。科网股全线走强，阿里巴巴、阿里健 康涨近5%，百度集团涨近2%。 ...

智通财经APP讯，漱玉平民(301017.SZ)发布公告，持股5%以上股东阿里健康科技(中国)有限公司(以下 简称"阿里健康")计划在本公告发布之日起15个交易日后的3个月内(即2026年2月4日至2026年4月30日)， 以集中竞价和/或大宗交易方式共计减持公司股份不超过810.72万股，占公司总股本的2%。 ...

每经AI快讯，漱玉平民1月13日晚间发布公告称，漱玉平民大药房连锁股份有限公司持股5%以上股东阿 里健康科技（中国）有限公司（简称"阿里健康"）持有公司股份约2704万股（占公司总股本比例为 6.67%），计划在本公告发布之日起15个交易日后的3个月内，以集中竞价和/或大宗交易方式共计减持 公司股份不超过约811万股，占公司总股本的2%。 （记者 王晓波） 每经头条（nbdtoutiao）——"春节也要加班，抢在4月1日前交货"！有光伏企业在抢出口，也有企业很 纠结：白银等原材料成本激增，决策困难 ...

漱玉平民（301017）(301017.SZ)发布公告，持股5%以上股东阿里健康科技(中国)有限公司(以下简称"阿 里健康")计划在本公告发布之日起15个交易日后的3个月内(即2026年2月4日至2026年4月30日)，以集中 竞价和/或大宗交易方式共计减持公司股份不超过810.72万股，占公司总股本的2%。 ...

漱玉平民公告，持股5%以上股东阿里健康持有公司2703.91万股，占6.67%，计划自本公告披露15个交 易日后的2026年2月4日至2026年4月30日，通过集中竞价和/或大宗交易合计减持不超810.72万股，占公 司总股本2%。其中集中竞价不超405.36万股，占1%，大宗交易不超405.36万股，占1%；减持原因为自 身资金需求，股份来源为首次公开发行前取得的股份。 ...

Core Insights - The article highlights a significant milestone in the treatment of infantile hemangiomas with the launch of a new drug, Malate Timolol Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after 12 years of research [1] - Beimeijing® is the first and only topical gel approved for the treatment of "proliferative superficial infantile hemangiomas," marking a key advancement for China in this medical field [1] - The drug has received authoritative certification from the national drug pricing management system, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Context - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The critical intervention period for effective treatment is within the first 1-6 months after birth, known as the "golden window," where timely treatment can prevent long-term skin issues [2] - Traditional treatment methods have faced limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - The development of Beimeijing® was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, involving a comprehensive process from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and non-invasive option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data supports the advantages of Beimeijing®, showing a clinical cure rate of 60.7% and an overall efficacy rate of 89.4% among 121 infants aged 1-6 months, with good safety profiles [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the needs of children, ensuring that the standardized treatment approach is effectively communicated to families [3]